– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension – – Coordinated reductions in biomarkers of fibrosis and heart failure suggest lorundrostat may favorably modulate the physiological processes that drive heart failure – RADNOR, Pa., June 14, 2026 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today presented new data on the effect of lorundrostat on heart failure (HF) risk biomarkers. This post hoc analysis of circulating proteomic...

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants – – Majority of verekitug-treated participants experienced clinically meaningful improvements across key secondary endpoints, including 72% in nasal congestion and 83% in CRSwNP total symptom score – WALTHAM, Mass., June 14, 2026 (GLOBE NEWSWIRE) — Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today presented new responder analyses from the Phase 2 VIBRANT trial of verekitug in participants with chronic rhinosinusitis with nasal polyps (CRSwNP). The findings were presented during an oral session at the European Academy of Allergy and Clinical Immunology (EAACI)...

Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSU Seven months after the completion of dosing (Week 76), up to 64% of patients treated with barzolvolimab who had angioedema at baseline remained angioedema-free Barzolvolimab has potential to shift treatment goals from symptom control to disease modification Results continue to support ongoing Phase 3 trials of barzolvolimab in CSU; topline data expected in Q4 2026HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) — Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. The data presented demonstrated that...

CDX-622 is a novel, bispecific antibody combining mast cell depletion and TSLP inhibition, two independent pathways contributing to multiple I&I diseases CDX-622 targets the soluble form of stem cell factor (SCF), depleting mast cells without measurably impacting other KIT functions Rapid, profound, dose-dependent, and durable reductions in serum tryptase observed Well-tolerated at all dose levels First company to demonstrate that neutralizing soluble SCF can selectively inhibit KIT signaling in mast cellsHAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) — Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that targets soluble SCF and TSLP, at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye....

 Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study Single infusion of LB2501 generated dose-dependent in vivo CAR-T expansion without lymphodepletion No dose-limiting toxicities, serious adverse events, ICANS, or deaths were reported; infusion-related reactions and CRS were Grade 1–2, and none required glucocorticoids for CRS management Additional translational data showed rapid vector clearance, polyclonal vector integration, and no evidence of non-specific transduction Proof-of-concept progress demonstrates leadership in next-generation cell therapies, with results presented in a late-breaking session at EHA 2026BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) — Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a...

Agreement covers more than 11,000 maintenance, airport airside, cargo, and administrative employees based in CanadaMONTRÉAL, June 13, 2026 (GLOBE NEWSWIRE) — Air Canada today said it has reached a tentative collective agreement with the International Association of Machinists and Aerospace Workers (IAMAW) representing more than 11,000 Air Canada employees in Maintenance, Cabin Services, Airport Airside Operations, Cargo, Finance and Clerical. The agreement recognizes the contributions and skills of Air Canada’s operations and administrative employees. Terms of the new agreement remain confidential pending ratification by the union membership, expected to be completed over the next few weeks, and approval by the Air Canada Board of Directors. About Air Canada Air Canada is Canada’s largest airline, the country’s flag...

Multi-organ system and quality-of-life benefits sustained through three and a half years  86% response rate for the multi-component endpoint 89% of patients completed the three-and-a-half-year trialCOPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium,...

Media Release COPENHAGEN, Denmark; June 13, 2026Results from the Phase 2 EPCORE® DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) ineligible for anthracycline-based chemotherapy Results from the Phase 1b/2 EPCORE® NHL-2 trial show fixed-duration epcoritamab plus standard of care R-mini-CHOP demonstrated sustained minimal residual disease (MRD) negativity and durable remissions in elderly patients with newly diagnosed DLBCL ineligible for full dose R-CHOP Data were presented at the 2026 European Hematology Association (EHA) CongressGenmab A/S (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously, in the first-line (1L) treatment of patients...

Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effects New analyses showed patients in mitapivat arm had clinically meaningful reduction in transfusion burden compared with placebo Patients in mitapivat arm who achieved hemoglobin response had clinically meaningful benefits across measures of sickle cell pain crises, fatigue, and other patient-reported outcomes Mitapivat was well-tolerated, with a safety profile consistent with previous trials of mitapivat in sickle cell disease Company to host investor conference call and webcast today at 9:00 a.m. ET (3:00 p.m. CEST)CAMBRIDGE, Mass., June 13, 2026 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative...

 — Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures —    — Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS — — Company to hold conference call on Saturday, June 13, at 8 a.m. CT, 9 a.m. ET — BOSTON, June 13, 2026 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced preliminary data from a Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome (PWS) delivered during the Endocrine Society’s Annual...